Share Price and Basic Stock Data
Last Updated: December 5, 2025, 6:23 pm
| PEG Ratio | -4.31 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
India Glycols Ltd operates within the chemicals sector, specifically focusing on organic and alcohol-based chemicals. As of its latest market valuation, the company’s share price stood at ₹1,070, with a market capitalization of ₹7,184 Cr. Over the past few quarters, India Glycols has exhibited a fluctuating sales trend, with revenues reported at ₹808 Cr in June 2022, declining to ₹554 Cr by December 2022. However, sales rebounded to ₹775 Cr in September 2023 and reached ₹904 Cr by December 2023, indicating a positive trajectory. The trailing twelve months (TTM) sales for the company were reported at ₹3,840 Cr. This growth trajectory is crucial as it reflects the company’s ability to navigate market challenges, particularly in a volatile chemicals sector where price fluctuations can impact revenues significantly.
Profitability and Efficiency Metrics
India Glycols has demonstrated a mixed performance in terms of profitability. The operating profit margin (OPM) fluctuated, reporting a peak of 17% in March 2025, while the net profit margin stood at 4.89% for the same period. The company reported a net profit of ₹244 Cr, which is an improvement from previous periods, showcasing its ability to enhance profitability despite rising operational costs. The interest coverage ratio (ICR) was recorded at 3.20x, indicating a stable capacity to cover interest expenses. However, the return on equity (ROE) was reported at 11.1%, which is relatively low compared to industry standards, suggesting that there is room for improvement in how effectively the company is utilizing shareholder equity. The cash conversion cycle (CCC) stood at 70 days, reflecting the time taken to convert investments in inventory and accounts receivable into cash flow.
Balance Sheet Strength and Financial Ratios
The balance sheet of India Glycols reveals a solid financial foundation, with total assets reported at ₹6,176 Cr as of March 2025. The company’s reserves have grown to ₹2,363 Cr, demonstrating its capacity to retain earnings for future growth. Borrowings stood at ₹2,055 Cr, leading to a total debt to equity ratio of 0.79, indicating a moderate leverage position. The book value per share was reported at ₹728.64, providing a clear insight into the intrinsic value of the company. Moreover, the current ratio was recorded at 0.78, suggesting potential liquidity challenges, while the quick ratio at 0.27 indicates a reliance on inventory to meet short-term obligations. These ratios highlight both strengths in asset management and potential caution regarding liquidity.
Shareholding Pattern and Investor Confidence
The shareholding structure of India Glycols reflects a significant level of promoter confidence, with promoters holding 59.63% of the equity as of November 2025. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) held 2.45% and 5.05%, respectively, indicating moderate institutional interest. The public shareholding stood at 32.86%, with a total of 54,774 shareholders. Notably, the number of shareholders increased from 42,869 in March 2023 to 54,774, suggesting growing retail investor interest. This rising shareholder base can be interpreted as a positive signal for the company’s future, as a diverse investor pool often enhances stability and market confidence. However, the decline in promoter shareholding from 61.02% in earlier quarters could raise concerns regarding insider confidence.
Outlook, Risks, and Final Insight
Looking ahead, India Glycols faces both opportunities and risks. The company’s ability to sustain revenue growth amid fluctuating raw material prices and global economic uncertainties will be critical. Key strengths include a robust operational framework and a growing shareholder base that enhances market confidence. However, risks such as high borrowing levels and relatively low ROE could impact future growth prospects. The company’s performance may hinge on its ability to manage costs effectively and optimize its capital structure. Should India Glycols successfully navigate these challenges, it could solidify its position within the organic chemicals sector, potentially enhancing shareholder value and profitability. Conversely, failure to address these risks may hinder its growth trajectory and affect market sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of India Glycols Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Aeonx Digital Technology Ltd | 82.8 Cr. | 180 | 323/121 | 27.6 | 115 | 0.56 % | 9.78 % | 6.79 % | 10.0 |
| Kanoria Chemicals & Industries Ltd | 325 Cr. | 74.4 | 127/71.0 | 122 | 0.00 % | 2.33 % | 11.8 % | 5.00 | |
| India Glycols Ltd | 7,184 Cr. | 1,070 | 1,223/502 | 27.7 | 387 | 0.47 % | 12.4 % | 11.1 % | 5.00 |
| Industry Average | 3,754.50 Cr | 441.47 | 27.65 | 208.00 | 0.34% | 8.17% | 9.90% | 6.67 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 808 | 670 | 554 | 619 | 689 | 775 | 904 | 926 | 969 | 961 | 975 | 863 | 1,040 |
| Expenses | 746 | 602 | 487 | 523 | 589 | 679 | 802 | 822 | 843 | 845 | 852 | 717 | 891 |
| Operating Profit | 63 | 68 | 67 | 96 | 100 | 96 | 102 | 105 | 126 | 116 | 124 | 146 | 150 |
| OPM % | 8% | 10% | 12% | 16% | 15% | 12% | 11% | 11% | 13% | 12% | 13% | 17% | 14% |
| Other Income | 16 | 9 | 35 | 6 | 12 | 12 | 9 | 10 | 14 | 15 | 19 | 13 | 20 |
| Interest | 22 | 24 | 27 | 26 | 28 | 29 | 31 | 33 | 36 | 40 | 44 | 45 | 45 |
| Depreciation | 21 | 21 | 21 | 30 | 21 | 28 | 26 | 26 | 28 | 28 | 27 | 33 | 34 |
| Profit before tax | 35 | 31 | 53 | 46 | 64 | 50 | 54 | 56 | 76 | 63 | 71 | 82 | 91 |
| Tax % | 20% | 25% | 6% | 13% | 20% | 24% | 23% | 24% | 20% | 22% | 20% | 22% | 19% |
| Net Profit | 28 | 24 | 50 | 40 | 51 | 38 | 42 | 42 | 60 | 50 | 57 | 64 | 73 |
| EPS in Rs | 4.69 | 4.04 | 4.96 | 6.51 | 8.26 | 6.14 | 6.73 | 6.82 | 9.75 | 8.03 | 9.18 | 10.34 | 11.83 |
Last Updated: August 20, 2025, 9:20 am
Below is a detailed analysis of the quarterly data for India Glycols Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,040.00 Cr.. The value appears strong and on an upward trend. It has increased from 863.00 Cr. (Mar 2025) to 1,040.00 Cr., marking an increase of 177.00 Cr..
- For Expenses, as of Jun 2025, the value is 891.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 717.00 Cr. (Mar 2025) to 891.00 Cr., marking an increase of 174.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 150.00 Cr.. The value appears strong and on an upward trend. It has increased from 146.00 Cr. (Mar 2025) to 150.00 Cr., marking an increase of 4.00 Cr..
- For OPM %, as of Jun 2025, the value is 14.00%. The value appears to be declining and may need further review. It has decreased from 17.00% (Mar 2025) to 14.00%, marking a decrease of 3.00%.
- For Other Income, as of Jun 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 7.00 Cr..
- For Interest, as of Jun 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 45.00 Cr..
- For Depreciation, as of Jun 2025, the value is 34.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 33.00 Cr. (Mar 2025) to 34.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 91.00 Cr.. The value appears strong and on an upward trend. It has increased from 82.00 Cr. (Mar 2025) to 91.00 Cr., marking an increase of 9.00 Cr..
- For Tax %, as of Jun 2025, the value is 19.00%. The value appears to be improving (decreasing) as expected. It has decreased from 22.00% (Mar 2025) to 19.00%, marking a decrease of 3.00%.
- For Net Profit, as of Jun 2025, the value is 73.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Mar 2025) to 73.00 Cr., marking an increase of 9.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 11.83. The value appears strong and on an upward trend. It has increased from 10.34 (Mar 2025) to 11.83, marking an increase of 1.49.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:09 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,977 | 2,579 | 2,324 | 2,500 | 3,034 | 3,357 | 2,735 | 2,317 | 2,868 | 2,651 | 3,294 | 3,768 | 3,840 |
| Expenses | 2,774 | 2,455 | 2,149 | 2,263 | 2,712 | 2,941 | 2,433 | 2,026 | 2,599 | 2,346 | 2,879 | 3,247 | 3,305 |
| Operating Profit | 203 | 124 | 175 | 237 | 322 | 416 | 303 | 291 | 269 | 305 | 415 | 521 | 535 |
| OPM % | 7% | 5% | 8% | 9% | 11% | 12% | 11% | 13% | 9% | 12% | 13% | 14% | 14% |
| Other Income | -174 | -16 | -47 | 7 | 23 | 17 | 24 | 15 | 260 | 54 | 30 | 51 | 67 |
| Interest | 150 | 163 | 139 | 127 | 125 | 143 | 97 | 83 | 70 | 100 | 121 | 164 | 173 |
| Depreciation | 91 | 89 | 69 | 72 | 73 | 76 | 78 | 80 | 80 | 94 | 101 | 115 | 122 |
| Profit before tax | -212 | -144 | -81 | 45 | 147 | 213 | 153 | 143 | 379 | 165 | 223 | 292 | 307 |
| Tax % | -24% | -38% | -30% | 22% | 34% | 38% | 25% | 8% | 10% | 15% | 23% | 21% | |
| Net Profit | -161 | -89 | -57 | 35 | 97 | 133 | 115 | 132 | 340 | 141 | 173 | 231 | 244 |
| EPS in Rs | -26.07 | -14.32 | -9.18 | 5.66 | 15.59 | 21.42 | 18.52 | 21.26 | 54.90 | 20.21 | 27.95 | 37.31 | 39.38 |
| Dividend Payout % | -2% | 0% | 0% | 9% | 13% | 14% | 16% | 14% | 7% | 19% | 14% | 13% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 44.72% | 35.96% | 161.40% | 177.14% | 37.11% | -13.53% | 14.78% | 157.58% | -58.53% | 22.70% | 33.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | -8.77% | 125.45% | 15.74% | -140.03% | -50.65% | 28.32% | 142.79% | -216.11% | 81.22% | 10.83% |
India Glycols Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 7% |
| 3 Years: | 10% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 12% |
| 3 Years: | 12% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 43% |
| 3 Years: | 26% |
| 1 Year: | 29% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 10% |
| 3 Years: | 9% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 7:00 am
Balance Sheet
Last Updated: December 4, 2025, 1:24 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 |
| Reserves | 341 | 266 | 687 | 721 | 814 | 932 | 1,003 | 1,138 | 1,761 | 1,870 | 2,020 | 2,225 | 2,363 |
| Borrowings | 2,053 | 2,264 | 1,236 | 1,095 | 834 | 1,000 | 999 | 1,137 | 1,047 | 1,112 | 1,348 | 1,892 | 2,055 |
| Other Liabilities | 818 | 593 | 1,665 | 1,645 | 1,742 | 1,821 | 2,053 | 1,814 | 1,792 | 1,845 | 2,218 | 2,029 | 1,709 |
| Total Liabilities | 3,243 | 3,154 | 3,620 | 3,492 | 3,421 | 3,784 | 4,086 | 4,119 | 4,631 | 4,858 | 5,617 | 6,176 | 6,157 |
| Fixed Assets | 1,309 | 1,146 | 2,029 | 2,111 | 2,156 | 2,173 | 2,228 | 2,193 | 2,318 | 2,717 | 3,205 | 3,829 | 3,754 |
| CWIP | 137 | 162 | 181 | 91 | 89 | 137 | 172 | 126 | 243 | 125 | 84 | 98 | 267 |
| Investments | 4 | 4 | 28 | 25 | 24 | 21 | 26 | 27 | 336 | 318 | 335 | 381 | 411 |
| Other Assets | 1,792 | 1,843 | 1,382 | 1,265 | 1,152 | 1,453 | 1,660 | 1,774 | 1,734 | 1,698 | 1,993 | 1,867 | 1,725 |
| Total Assets | 3,243 | 3,154 | 3,620 | 3,492 | 3,421 | 3,784 | 4,086 | 4,119 | 4,631 | 4,858 | 5,617 | 6,176 | 6,157 |
Below is a detailed analysis of the balance sheet data for India Glycols Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 31.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,363.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,225.00 Cr. (Mar 2025) to 2,363.00 Cr., marking an increase of 138.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,055.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,892.00 Cr. (Mar 2025) to 2,055.00 Cr., marking an increase of 163.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,709.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,029.00 Cr. (Mar 2025) to 1,709.00 Cr., marking a decrease of 320.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 6,157.00 Cr.. The value appears to be improving (decreasing). It has decreased from 6,176.00 Cr. (Mar 2025) to 6,157.00 Cr., marking a decrease of 19.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3,754.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,829.00 Cr. (Mar 2025) to 3,754.00 Cr., marking a decrease of 75.00 Cr..
- For CWIP, as of Sep 2025, the value is 267.00 Cr.. The value appears strong and on an upward trend. It has increased from 98.00 Cr. (Mar 2025) to 267.00 Cr., marking an increase of 169.00 Cr..
- For Investments, as of Sep 2025, the value is 411.00 Cr.. The value appears strong and on an upward trend. It has increased from 381.00 Cr. (Mar 2025) to 411.00 Cr., marking an increase of 30.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,725.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,867.00 Cr. (Mar 2025) to 1,725.00 Cr., marking a decrease of 142.00 Cr..
- For Total Assets, as of Sep 2025, the value is 6,157.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,176.00 Cr. (Mar 2025) to 6,157.00 Cr., marking a decrease of 19.00 Cr..
Notably, the Reserves (2,363.00 Cr.) exceed the Borrowings (2,055.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 201.00 | 122.00 | 174.00 | 236.00 | -512.00 | 415.00 | -696.00 | 290.00 | 268.00 | 304.00 | 414.00 | 520.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54 | 62 | 57 | 57 | 40 | 35 | 76 | 57 | 51 | 59 | 43 | 35 |
| Inventory Days | 109 | 109 | 128 | 129 | 87 | 124 | 146 | 166 | 148 | 209 | 224 | 209 |
| Days Payable | 91 | 55 | 120 | 144 | 152 | 143 | 155 | 158 | 137 | 209 | 222 | 175 |
| Cash Conversion Cycle | 72 | 115 | 66 | 42 | -25 | 17 | 67 | 65 | 62 | 60 | 44 | 70 |
| Working Capital Days | -58 | -110 | -94 | -117 | -78 | -50 | -64 | -79 | -31 | -46 | -63 | -56 |
| ROCE % | 5% | 3% | 5% | 9% | 15% | 20% | 14% | 10% | 9% | 8% | 11% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal Nifty Microcap 250 Index Fund | 11,667 | 0.17 | 0.78 | 11,667 | 2025-04-22 17:25:31 | 0% |
| Groww Nifty Total Market Index Fund | 27 | 0.01 | 0 | 27 | 2025-04-22 17:25:31 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 74.58 | 55.87 | 45.55 | 109.77 | 42.51 |
| Diluted EPS (Rs.) | 74.58 | 55.87 | 45.55 | 109.77 | 42.51 |
| Cash EPS (Rs.) | 96.81 | 83.04 | 72.23 | 128.95 | 68.15 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 728.64 | 662.44 | 614.12 | 572.46 | 377.41 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 728.64 | 662.44 | 614.12 | 572.46 | 377.41 |
| Revenue From Operations / Share (Rs.) | 1217.14 | 1063.89 | 856.18 | 926.41 | 748.35 |
| PBDIT / Share (Rs.) | 169.73 | 138.26 | 103.17 | 89.38 | 91.49 |
| PBIT / Share (Rs.) | 132.52 | 105.72 | 72.82 | 63.45 | 65.61 |
| PBT / Share (Rs.) | 79.43 | 66.74 | 49.62 | 112.44 | 38.68 |
| Net Profit / Share (Rs.) | 59.60 | 50.49 | 41.88 | 103.02 | 42.27 |
| NP After MI And SOA / Share (Rs.) | 74.59 | 55.87 | 40.40 | 109.77 | 42.51 |
| PBDIT Margin (%) | 13.94 | 12.99 | 12.04 | 9.64 | 12.22 |
| PBIT Margin (%) | 10.88 | 9.93 | 8.50 | 6.84 | 8.76 |
| PBT Margin (%) | 6.52 | 6.27 | 5.79 | 12.13 | 5.16 |
| Net Profit Margin (%) | 4.89 | 4.74 | 4.89 | 11.12 | 5.64 |
| NP After MI And SOA Margin (%) | 6.12 | 5.25 | 4.71 | 11.84 | 5.68 |
| Return on Networth / Equity (%) | 10.23 | 8.43 | 6.57 | 18.96 | 11.26 |
| Return on Capital Employeed (%) | 10.64 | 10.09 | 7.53 | 6.81 | 8.63 |
| Return On Assets (%) | 3.73 | 3.07 | 2.57 | 7.33 | 3.19 |
| Long Term Debt / Equity (X) | 0.46 | 0.35 | 0.28 | 0.30 | 0.43 |
| Total Debt / Equity (X) | 0.79 | 0.64 | 0.57 | 0.58 | 0.84 |
| Asset Turnover Ratio (%) | 0.63 | 0.62 | 0.55 | 0.68 | 0.55 |
| Current Ratio (X) | 0.78 | 0.81 | 0.88 | 0.91 | 0.96 |
| Quick Ratio (X) | 0.27 | 0.35 | 0.47 | 0.52 | 0.62 |
| Inventory Turnover Ratio (X) | 2.06 | 1.96 | 2.00 | 2.57 | 1.84 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 13.42 | 18.56 | 5.46 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 8.48 | 10.60 | 4.42 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 86.58 | 81.44 | 94.54 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 91.52 | 89.40 | 95.58 | 0.00 |
| Interest Coverage Ratio (X) | 3.20 | 3.55 | 3.20 | 3.97 | 3.40 |
| Interest Coverage Ratio (Post Tax) (X) | 2.12 | 2.30 | 2.02 | 2.25 | 2.30 |
| Enterprise Value (Cr.) | 5163.54 | 3526.29 | 2881.37 | 4053.87 | 2184.04 |
| EV / Net Operating Revenue (X) | 1.37 | 1.07 | 1.09 | 1.41 | 0.94 |
| EV / EBITDA (X) | 9.83 | 8.24 | 9.02 | 14.65 | 7.71 |
| MarketCap / Net Operating Revenue (X) | 0.91 | 0.71 | 0.71 | 1.09 | 0.55 |
| Retention Ratios (%) | 0.00 | 86.57 | 81.43 | 94.53 | 0.00 |
| Price / BV (X) | 1.52 | 1.14 | 0.99 | 1.75 | 1.10 |
| Price / Net Operating Revenue (X) | 0.91 | 0.71 | 0.71 | 1.09 | 0.55 |
| EarningsYield | 0.06 | 0.07 | 0.06 | 0.10 | 0.10 |
After reviewing the key financial ratios for India Glycols Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 74.58. This value is within the healthy range. It has increased from 55.87 (Mar 24) to 74.58, marking an increase of 18.71.
- For Diluted EPS (Rs.), as of Mar 25, the value is 74.58. This value is within the healthy range. It has increased from 55.87 (Mar 24) to 74.58, marking an increase of 18.71.
- For Cash EPS (Rs.), as of Mar 25, the value is 96.81. This value is within the healthy range. It has increased from 83.04 (Mar 24) to 96.81, marking an increase of 13.77.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 728.64. It has increased from 662.44 (Mar 24) to 728.64, marking an increase of 66.20.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 728.64. It has increased from 662.44 (Mar 24) to 728.64, marking an increase of 66.20.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,217.14. It has increased from 1,063.89 (Mar 24) to 1,217.14, marking an increase of 153.25.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 169.73. This value is within the healthy range. It has increased from 138.26 (Mar 24) to 169.73, marking an increase of 31.47.
- For PBIT / Share (Rs.), as of Mar 25, the value is 132.52. This value is within the healthy range. It has increased from 105.72 (Mar 24) to 132.52, marking an increase of 26.80.
- For PBT / Share (Rs.), as of Mar 25, the value is 79.43. This value is within the healthy range. It has increased from 66.74 (Mar 24) to 79.43, marking an increase of 12.69.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 59.60. This value is within the healthy range. It has increased from 50.49 (Mar 24) to 59.60, marking an increase of 9.11.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 74.59. This value is within the healthy range. It has increased from 55.87 (Mar 24) to 74.59, marking an increase of 18.72.
- For PBDIT Margin (%), as of Mar 25, the value is 13.94. This value is within the healthy range. It has increased from 12.99 (Mar 24) to 13.94, marking an increase of 0.95.
- For PBIT Margin (%), as of Mar 25, the value is 10.88. This value is within the healthy range. It has increased from 9.93 (Mar 24) to 10.88, marking an increase of 0.95.
- For PBT Margin (%), as of Mar 25, the value is 6.52. This value is below the healthy minimum of 10. It has increased from 6.27 (Mar 24) to 6.52, marking an increase of 0.25.
- For Net Profit Margin (%), as of Mar 25, the value is 4.89. This value is below the healthy minimum of 5. It has increased from 4.74 (Mar 24) to 4.89, marking an increase of 0.15.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.12. This value is below the healthy minimum of 8. It has increased from 5.25 (Mar 24) to 6.12, marking an increase of 0.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.23. This value is below the healthy minimum of 15. It has increased from 8.43 (Mar 24) to 10.23, marking an increase of 1.80.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.64. This value is within the healthy range. It has increased from 10.09 (Mar 24) to 10.64, marking an increase of 0.55.
- For Return On Assets (%), as of Mar 25, the value is 3.73. This value is below the healthy minimum of 5. It has increased from 3.07 (Mar 24) to 3.73, marking an increase of 0.66.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.46. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 0.46, marking an increase of 0.11.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.79. This value is within the healthy range. It has increased from 0.64 (Mar 24) to 0.79, marking an increase of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.63. It has increased from 0.62 (Mar 24) to 0.63, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1.5. It has decreased from 0.81 (Mar 24) to 0.78, marking a decrease of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has decreased from 0.35 (Mar 24) to 0.27, marking a decrease of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.06. This value is below the healthy minimum of 4. It has increased from 1.96 (Mar 24) to 2.06, marking an increase of 0.10.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 13.42 (Mar 24) to 0.00, marking a decrease of 13.42.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 8.48 (Mar 24) to 0.00, marking a decrease of 8.48.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 86.58 (Mar 24) to 0.00, marking a decrease of 86.58.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 91.52 (Mar 24) to 0.00, marking a decrease of 91.52.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.20. This value is within the healthy range. It has decreased from 3.55 (Mar 24) to 3.20, marking a decrease of 0.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.12. This value is below the healthy minimum of 3. It has decreased from 2.30 (Mar 24) to 2.12, marking a decrease of 0.18.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,163.54. It has increased from 3,526.29 (Mar 24) to 5,163.54, marking an increase of 1,637.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has increased from 1.07 (Mar 24) to 1.37, marking an increase of 0.30.
- For EV / EBITDA (X), as of Mar 25, the value is 9.83. This value is within the healthy range. It has increased from 8.24 (Mar 24) to 9.83, marking an increase of 1.59.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has increased from 0.71 (Mar 24) to 0.91, marking an increase of 0.20.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 86.57 (Mar 24) to 0.00, marking a decrease of 86.57.
- For Price / BV (X), as of Mar 25, the value is 1.52. This value is within the healthy range. It has increased from 1.14 (Mar 24) to 1.52, marking an increase of 0.38.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has increased from 0.71 (Mar 24) to 0.91, marking an increase of 0.20.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.06, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in India Glycols Ltd:
- Net Profit Margin: 4.89%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.64% (Industry Average ROCE: 8.17%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.23% (Industry Average ROE: 9.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.12
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.27
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 27.7 (Industry average Stock P/E: 18.43)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.79
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.89%
About the Company - India Glycols Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Alcohol Based | A-1, Industrial Area, Bazpur Road, Udham Singh Nagar Uttarakhand/Uttaranchal 244713 | compliance.officer@indiaglycols.com http://www.indiaglycols.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. U S Bhartia | Chairman & Managing Director |
| Mr. Sudhir Agarwal | Executive Director |
| Mr. Pragya Bhartia Barwale | Executive Director |
| Mr. Pradip Kumar Khaitan | Independent Director |
| Mr. Jitender Balakrishnan | Independent Director |
| Mr. Ravi Jhunjhunwala | Independent Director |
| Mr. Jagmohan N Kejriwal | Independent Director |
| Ms. Shukla Wasson | Independent Director |
| Mrs. Jayshree Bhartia | Director |
India Glycols Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹789.95 |
| Previous Day | ₹799.85 |
FAQ
What is the intrinsic value of India Glycols Ltd?
India Glycols Ltd's intrinsic value (as of 06 December 2025) is 956.40 which is 10.62% lower the current market price of 1,070.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 7,184 Cr. market cap, FY2025-2026 high/low of 1,223/502, reserves of ₹2,363 Cr, and liabilities of 6,157 Cr.
What is the Market Cap of India Glycols Ltd?
The Market Cap of India Glycols Ltd is 7,184 Cr..
What is the current Stock Price of India Glycols Ltd as on 06 December 2025?
The current stock price of India Glycols Ltd as on 06 December 2025 is 1,070.
What is the High / Low of India Glycols Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of India Glycols Ltd stocks is 1,223/502.
What is the Stock P/E of India Glycols Ltd?
The Stock P/E of India Glycols Ltd is 27.7.
What is the Book Value of India Glycols Ltd?
The Book Value of India Glycols Ltd is 387.
What is the Dividend Yield of India Glycols Ltd?
The Dividend Yield of India Glycols Ltd is 0.47 %.
What is the ROCE of India Glycols Ltd?
The ROCE of India Glycols Ltd is 12.4 %.
What is the ROE of India Glycols Ltd?
The ROE of India Glycols Ltd is 11.1 %.
What is the Face Value of India Glycols Ltd?
The Face Value of India Glycols Ltd is 5.00.